Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Historical Data Period | 2020 - 2024 |
| Base Year Market Size (2025) | USD 123.05 Million |
| Market Size (2026) | USD 129.25 Million |
| Market Size (2031) | USD 165.17 Million |
| Growth Rate (2026 - 2031) | 5.04% CAGR |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Latin America Insulin Infusion Pump Market Analysis by Mordor Intelligence
Latin America Insulin Infusion Pump Market size market size in 2026 is estimated at USD 129.25 million, growing from 2025 value of USD 123.05 million with 2031 projections showing USD 165.17 million, growing at 5.04% CAGR over 2026-2031.
The pandemic that everyone was talking about before COVID-19, is a challenge to health systems and a threat to their financial viability. The improper use of corticosteroids and the presence of diabetes mellitus in patients during the Coronavirus Disease 2019 (COVID-19) pandemic marked the beginning of an increased incidence of fungal infections such as aspergillosis and mucormycosis in patients with this emerging viral infection. More than 200 cases have been reported in the literature in Latin America, ranging from Mexico to Argentina. Most cases have come from Brazil. Before COVID-19, the number of cases had been increasing while the mortality rate had been decreasing. Access to telemedicine is critical for managing chronic diseases in children, such as type 1 diabetes. Telemedicine was implemented in Latin American countries because of the COVID-19 pandemic, which had a positive impact on the health system. Telemedicine could result in financial savings by avoiding transportation expenses, class and parental working hours lost, time lost for transportation to distant referral health centers, and improving the quality of life, socioeconomic level, and environment."
An insulin pump (also known as continuous subcutaneous insulin therapy) is a medical device used to administer insulin to treat diabetes. Insulin pumps make it possible to deliver continuous infusion amounts of insulin at regular intervals. It is predicted to result in long-term cost savings relative to multiple daily injections. The traditional pump includes the pump (including controls, a processing module, and batteries), a disposable reservoir for insulin (inside the pump), and a disposable infusion set, including a cannula for subcutaneous insertion (under the skin) and a tubing system to connect the insulin reservoir to the cannula. The device configuration may vary depending on the design. However, the application of infusion pumps is increasing significantly across the Latin American region.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Latin America Insulin Infusion Pump Market Trends and Insights
Insulin Pump Monitors Hold Highest Market Share in Latin America Insulin Infusion Pump Market in the current year
In Latin America, a variety of insulin pumps are available. Traditional insulin pumps have an insulin reservoir (or container) and pumping mechanism attached to the body with tubing and an infusion set. The other insulin patch pumps are worn directly on the body and have a reservoir, pumping mechanism, and infusion set inside a small case. Patch pumps are controlled wirelessly by a separate device that allows the programming of insulin delivery for meals from the patch. Most insurance companies in Latin America cover insulin pump therapy with variable out-of-pocket expenses. Diabetes is one of the major health challenges of the twenty-first century, according to the Pan American Health Organization (PAHO). According to the organization's data, the number of people suffering from this condition will reach 642 million by 2040. One advantage of this solution is that it allows patients to communicate with a remote healthcare professional, avoiding the need to visit a healthcare facility and lowering the risk of contracting COVID-19 in this high-risk group. Diabetes affects approximately 41 million people in Latin America and 400 million worldwide. This figure is expected to rise over time, reaching 68 million diabetics in the region by 2040.
The overall prevalence of insulin pump use increased from 30% in 2001-2005 to 58.3% in 2016-2019; there was no change in rates by race, income, or education over time. The technology combines glucose monitoring using a CGM with advanced algorithms in the insulin pump to predict low glucose and suspend insulin delivery. The technological innovation in the insulin pump device market is likely to drive the market during the forecast period.
Brazil Holds Highest Market Share in Latin America Insulin Infusion Pump Market in the current year
The MOH governs the Brazilian health system, which each state and local health secretariat manages. Furthermore, in many towns where the public sector cannot meet people's needs, partnerships with private organizations have been established to increase access to PHC. Several programs in the Brazilian health system cover medicines, including a 20% increase in access to essential medicines. Brazil offers a comprehensive free immunization program. Over the last two decades, Brazil has faced many lawsuits demanding that high-priced drugs used to treat diabetes and other rare or low-prevalence diseases be covered. Between 2017 and 2045, the diabetic population in Brazil is expected to increase by 74%. Brazil is the world's sixth most populous country, with the fourth highest diabetes prevalence. To reduce the country's death rate, the Brazilian government is encouraging diabetes patients to take medication. The Brazilian Ministry of Health collaborated with private pharmacies in Brazil to provide free insulin (regular human insulin and isophane insulin or NPH) and three oral diabetes medications (5 mg glibenclamide and 500 and 850 mg metformin). According to a Brazilian survey, 38.4% of people with diabetes are delaying medical appointments or laboratory tests, and 5.8% have stopped reclaiming their diabetes self-care medicines and medical supplies. The potential consequences of these fears on diabetic populations can be disastrous, increasing the already high incidence of chronic complications and exacerbating their risk of SARS-CoV-2 infection. As a result, among the immediate safeguards, the government began telehealth, teleconsultation, and other online strategies to address the challenges of healthcare professional shortages while keeping people with diabetes safe and assisted. Brazil is expected to dominate the market due to the easy availability of insulin delivery devices, high consumer awareness, and reimbursement policies.
Therefore, owing to the factors above, the growth of the studied market is anticipated in the Latin America Region.
Competitive Landscape
The new technologies in Insulin Infusion Pump devices increased the market for Insulin Pump devices. Animas had to exit the insulin pump market owing to the rising competition. Medtronic is the market leader and is expected to maintain its position during the forecast period.
Latin America Insulin Infusion Pump Industry Leaders
Roche
Ypsomped
Insulet
Medtronic
Tandem
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Opportunities in Latin America are tied to improving device availability and service coverage as diabetes care continues to move toward connected, home-based models, including tubeless patch pump therapy and pump-plus-monitoring bundles. Insulet's announced plan (January 2026) to establish a diabetes-device manufacturing plant in Costa Rica, with an investment reported at over USD 200 million, is a concrete supply-side catalyst that adds regional manufacturing capacity and supports faster replenishment of consumables and broader channel coverage across Latin America.
Demand-side traction also hinges on telemedicine adoption for chronic disease management and on endocrinology capacity concentrated in major urban hubs such as Mexico City and Sao Paulo. Together, these factors support structured pump initiation and follow-up programs, including premium service bundles that pair devices with training and remote monitoring. At the same time, access beyond top-tier private centers still faces constraints from variable reimbursement and out-of-pocket costs, leaving room for suppliers to localize patient support, education, and distribution models across Brazil, Mexico, and the rest of Latin America.
Recent Industry Developments
- June 2026: Medtronic reports an academic study in Latin America on three-year glycemic outcomes for MiniMed 780G users across Chile, Argentina, Brazil, and Mexico. The results provide real world performance data for the region and reinforce the technology's clinical relevance. The study supports continued adoption of advanced insulin delivery in Latin American markets by showing sustained efficacy in routine use.
- May 2026: Medtronic is subject to INVIMA alert 118-2026 regarding software for the SynchroMed infusion pump clinician programmer. The alert highlights regulatory scrutiny for infusion pump software in Latin America. It points to heightened oversight that could affect product deployment timing and after-sales compliance in the region.
- January 2026: Insulet announces plans to establish a manufacturing plant in Costa Rica to produce medical devices for diabetes care. The project builds a regional manufacturing hub for diabetes devices. It improves the regional supply chain and may strengthen price and availability advantages for Latin American customers.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers the revenues generated from insulin infusion pumps and their related supply components sold for diabetes management across Latin America, including device hardware and recurring consumables purchased through hospitals, clinics, pharmacies, and distributor channels.
Scope exclusions: We exclude insulin drugs, glucose monitoring devices, general diabetes test strips, and broader diabetes management software that is not bundled with the infusion pump system.
Segmentation Overview
- Device
- Insulin Pump Monitors
- Insulin Infusion Pump
- Reserviour
- Geography
- Mexico
- Brazil
- Rest of Latin America
Data Sources, Market Sizing, and Validation
Desk Research
Desk research was used to build the base demand pool and to understand how insulin pump therapy is being adopted across Latin American health systems. We referred to public health statistics and policy documents that help track diabetes burden and treatment access, such as WHO health profiles, International Diabetes Federation (IDF) diabetes atlas releases, PAHO updates, and national health ministry publications from larger countries in the region.
To align the model with market reality, we also reviewed customs and trade statistics (where available), medical device regulatory notices, and reimbursement and tender information published by public agencies. Supplier annual reports, distributor announcements, and reputable press coverage were used to confirm product launches, channel shifts, and supply continuity, followed by selective checks from paid subscriptions that compile company financials, news, patent activity, and public tenders in a standardized format. These examples are not exhaustive, and additional sources were reviewed to collect data points, validate assumptions, and clarify open questions.
Primary Interviews and Surveys
Primary work focused on cross-checking the adoption curve, pricing behavior, and channel mix for pumps and consumables in Latin America, where access and reimbursement can vary widely by country. We spoke with a mix of device distributors, hospital procurement stakeholders, diabetes clinicians, and payer-informed respondents across major markets and smaller countries to confirm utilization patterns and to pressure-test assumptions that desk sources do not consistently disclose.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 34% | CXOs: 15% | |
| Mid tier: 45% | Functional/Unit leaders: 27% | |
| Smaller Players: 21% | Managers: 58% |
Market-Sizing & Forecasting
For sizing, the main build uses a top-down approach where the diabetes population and insulin treated pool are reconstructed by country, then filtered through pump therapy penetration and typical replacement and resupply cycles. The model is corroborated with selective bottom-up checks, including sampled channel sell-in signals, country-level shipment indicators where observable, and an ASP times volume sanity check for pump devices and recurring infusion sets and reservoirs.
Key inputs used to keep the numbers grounded include diagnosed diabetes prevalence trends, type 1 versus insulin-intensive cohorts, pump user penetration by care setting, component replacement frequency (infusion sets and reservoirs), import dependence signals, and observed pricing dispersion across private and public channels. Where country data was thin, gaps were handled through proxying from similar markets in the region, then adjusted using interview feedback on access constraints, reimbursement breadth, and distributor coverage.
Forecasting was built using scenario analysis supported by short time-series smoothing, since adoption is affected by policy steps, tender timing, and price resets that do not always move in a straight line. In each scenario, drivers were updated using expert consensus on expected penetration change, component attach rates, and realistic ASP progression by currency and inflation context.
Data Validation & Update Cycle
Validation is done through triangulation across independent signals, followed by variance checks that flag unusual jumps in penetration, pricing, or component shares by country. When anomalies appear, we revisit assumptions, re-check the underlying sources, and re-contact respondents if the gap is large enough to change the final view.
Before sign-off, the model goes through multiple analyst reviews so unit logic, currency conversions, and country roll-ups match the stated scope. Reports are refreshed annually, with interim updates when material events occur, including reimbursement changes, major supply shifts, or notable pricing resets. Before delivery, a final update pass is completed so clients receive the latest version of the model outputs.
Mordor Intelligence's Latin America Insulin Infusion Pump Market Size Compared Against Other Published Estimates
Published market values for insulin infusion pumps in Latin America often do not match because the scope and timing choices differ, even when the titles look similar. Common differences come from whether only the pump device is counted or whether recurring components are included, and from how local currency pricing is converted into USD across volatile periods.
In this study, the refresh cadence and currency timing were tied to the most recent observable pricing resets and interview-validated ASP steps for pumps and consumables, which is why the 2025 value lands where it does in Mordor Intelligence.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 123.05 M (2025) | |
| Regional Consultancy A | USD 108.40 M (2025) | Often counts mainly pump devices and applies a flatter ASP curve, which can understate the recurring infusion set and reservoir revenue contribution in markets with active replacement cycles. |
| Industry Association B | USD 140.90 M (2026) | Uses a broader demand assumption for pump adoption and may rely on earlier-year FX averages, which can inflate USD totals when local pricing and reimbursement updates are not refreshed at the same pace. |
The spread across the three figures mainly tracks back to what is counted (device only versus device plus consumables) and to how pricing and FX are handled when rolling up countries. Our approach keeps the steps traceable to adoption, replacement cadence, and updated pricing checks, so it is easier to reproduce the estimate and to explain shifts as new policy and tender events occur.
Key Questions Answered in the Report
How big is the Latin America Insulin Infusion Pump Market?
The Latin America Insulin Infusion Pump Market size is expected to reach USD 129.25 million in 2026 and grow at a CAGR of 5.04% to reach USD 165.17 million by 2031.
What is the current Latin America Insulin Infusion Pump Market size?
In 2026, the Latin America Insulin Infusion Pump Market size is expected to reach USD 129.25 million.
Who are the key players in Latin America Insulin Infusion Pump Market?
Roche, Ypsomped, Insulet, Medtronic and Tandem are the major companies operating in the Latin America Insulin Infusion Pump Market.
What years does this Latin America Insulin Infusion Pump Market cover, and what was the market size in 2025?
In 2025, the Latin America Insulin Infusion Pump Market size was estimated at USD 123.05 million. The report covers the Latin America Insulin Infusion Pump Market historical market size for years: 2019, 2020, 2021, 2022, 2023, 2024 and 2025. The report also forecasts the Latin America Insulin Infusion Pump Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
